Pineda, Elmor D.
To, Tu My
Dickendesher, Travis L.
Shapouri, Sheila
Iannaccone, Susan T.
Funding for this research was provided by:
Genentech Inc, South San Francisco, CA, USA.
Article History
Received: 24 January 2024
Accepted: 20 March 2024
First Online: 6 May 2024
Declarations
:
: Elmor D. Pineda, Tu My To, Travis Dickendesher, and Sheila Shapouri are employees of Genentech Inc and shareholders of F. Hoffmann-La Roche Ltd. Susan T. Iannaccone has received funding from the National Institutes of Health, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, Cure SMA, Department of Defense, AveXis, Biogen, PTC Therapeutics, Sarepta, FibroGen, Pfizer and ScholarRock.
: The present study made use of deidentified data and was thus exempt from the institutional review board review. This research was compliant with the Health Insurance Portability and Accountability Act. Genentech, Inc, has a data use agreement with the specialty pharmacy utilized in this study, which allows Genentech-associated researchers to use and analyze their data and to publish the corresponding results.